How will INVEST and other XXXX trials change clinical practice?

@entity1 @entity64 @entity101 @entity6 @entity583 @entity2299 @entity4324 @entity299 @entity453
Three large, ongoing, international clinical trials will greatly improve our understanding of @entity101 management. The trials, which include the INternational VErapamil SR/trandolapril STudy (INVEST), the Antihypertensive and Lipid Lowering Treatment to Prevent @entity299 Trial (ALLHAT), and the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial, enrolled a combined total of 81,649 @entity1 over a 7-year period from 18 different @entity4324 , South America, Europe, and Australia-Asia. The mean age of all subjects was 66 years, and the mean body mass index (BMI) was 29.5. In addition, 30% of all @entity1 had @entity6 and 43% had documented @entity453 ( @entity453 ). In INVEST, 100% of enrolled @entity1 had documented @entity453 and 27% had @entity6 . Of @entity1 treated for 12 months in INVEST, a systolic blood pressure (SBP) <140 mmHg was achieved by 70% of nondiabetics, and 66% of @entity1 with @entity6 achieved that level. Of all the @entity1 enrolled in the three trials, 38% were smokers, 25% had a history of @entity583 ( @entity583 ) or @entity64 , and 52% had a history of @entity2299 . Although these clinical trials are likely to influence treatment guidelines, they may not affect the way medicine is practiced. A survey of primary care physicians found that 41% had not heard of or were not familiar with the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) guidelines. The JNC VI and European guidelines provide management strategies based on severity of coronary risk factors, target organ damage, and blood pressure levels. Primary care physicians have a responsibility to be educated about risk stratification, goals of treatment based on risk, and management strategies for @entity101 from available treatment guidelines.
